Exact Sciences halted ahead of FDA panel meeting for Cologuard Exact Sciences' (EXAS) shares have been halted ahead of a meeting of an FDA committee to discuss the company's premarket approval application for its Cologuard screening test for colorectal cancer. The panel is due to start the meeting at 8 am ET. Trial results showed that compared with colonoscopy, the test is 92% sensitive for cancer stages I and II, and 69% for precancerous polyps containing high-grade dysplasia (highest cancer risk).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.